Tengjun Biotechnology Corp. Operating Costs and Expenses
Tengjun Biotechnology Corp. reported Operating Costs and Expenses of $417.33 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingCostsAndExpenses · last filed 2023-08-15
- Tengjun Biotechnology Corp. operating costs and expenses for the quarter ending 2023-06-30 was $417.33K, a 99.03% decline year-over-year.
- Tengjun Biotechnology Corp. operating costs and expenses for the quarter ending 2023-03-31 was $7.42M, a 106.75% increase year-over-year.
- Tengjun Biotechnology Corp. operating costs and expenses for the quarter ending 2022-12-31 was $48.46M, a 29588.38% increase year-over-year.
- Tengjun Biotechnology Corp. operating costs and expenses for the quarter ending 2022-09-30 was $29.20M, a 27049.72% increase year-over-year.
- Tengjun Biotechnology Corp. operating costs and expenses for fiscal 2022 was $124.35M, a 18987.67% increase from fiscal 2021.
- Tengjun Biotechnology Corp. operating costs and expenses for fiscal 2021 was $651.47K, a 2.28% decline from fiscal 2020.
- Tengjun Biotechnology Corp. operating costs and expenses for fiscal 2020 was $666.68K.
| Period end | Operating Costs and Expenses 3 month | Operating Costs and Expenses 3 month as first filed | Operating Costs and Expenses 6 month | Operating Costs and Expenses 6 month as first filed | Operating Costs and Expenses 9 month | Operating Costs and Expenses 12 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $417.33K 10-Q · filed 2023-08-15 | $7.84M 10-Q · filed 2023-08-15 | $56.30M derived: sum of 3 quarters · filed 2023-08-15 | $85.50M derived: sum of 4 quarters · filed 2023-08-15 | ||
| 2023-03-31 | $7.42M 10-Q · filed 2023-05-15 | $55.88M derived: sum of 2 quarters · filed 2023-05-15 | $85.08M derived: sum of 3 quarters · filed 2023-05-15 | $128.23M derived: sum of 4 quarters · filed 2023-08-15 | ||
| 2022-12-31 | $48.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $77.66M derived: sum of 2 quarters · filed 2023-04-17 | $120.81M derived: sum of 3 quarters · filed 2023-08-15 | $124.35M 10-K · filed 2023-04-17 | ||
| 2022-09-30 | $29.20M 10-Q · filed 2022-11-14 | $72.34M derived: sum of 2 quarters · filed 2023-08-15 | $75.89M 10-Q · filed 2022-11-14 | $76.10M derived: sum of 4 quarters · filed 2023-08-15 | ||
| 2022-06-30 | $43.14M 10-Q · filed 2023-08-15 | $51.26M 10-Q · filed 2022-08-15 | $46.69M 10-Q · filed 2023-08-15 | $54.81M 10-Q · filed 2022-08-15 | $46.90M derived: sum of 3 quarters · filed 2023-08-15 | $47.00M derived: sum of 4 quarters · filed 2023-08-15 |
| 2022-03-31 | $3.59M 10-Q · filed 2023-05-15 | $3.54M 10-Q · filed 2022-05-13 | $3.75M derived: sum of 2 quarters · filed 2023-05-15 | $3.86M derived: sum of 3 quarters · filed 2023-05-15 | $4.08M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $163.24K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $270.79K derived: sum of 2 quarters · filed 2023-04-17 | $490.21K derived: sum of 3 quarters · filed 2023-04-17 | $651.47K 10-K · filed 2023-04-17 | ||
| 2021-09-30 | $107.55K 10-Q · filed 2022-11-14 | $326.97K derived: sum of 2 quarters · filed 2022-11-14 | $488.23K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $219.42K 10-Q/A · filed 2022-09-16 | $380.55K 10-Q/A · filed 2022-09-16 | ||||
| 2021-03-31 | $161.13K 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $666.68K 10-K · filed 2022-03-31 |